TO THE EDITOR
Azathioprine is an antimetabolite drug widely used for immunosuppression in post-transplantation regimen and various autoimmune disorders. Although azathioprine commonly produces a variety of hematological abnormalities, including megaloblastic changes and marrow suppression, the incidence of therapy-related myelodysplastic syndromes (t-MDS) or acute myeloid leukemia (AML) is admittedly very low. However, a few cases of t-MDS or AML following prolonged azathioprine treatment have been reported. [1] [2] [3] [4] [5] When available, cytogenetic analysis showed mainly 5 and 7 abnormalities. The 17pÀ syndrome represents a morphological-cytogenetic entity among MDS characterized by a specific type of dysgranulopoiesis and P53 mutation. About one-half of cases occur after prolonged use of alkylating agents and generally carry À7/del 7q. The other half occur after essential thrombocythemia and polycythemia vera treated by hydroxyurea or other nonalkylating agents, and usually have no À7/del 7q. 6 We describe here a case of therapyrelated refractory anemia following long-term azathioprine treatment with 17pÀ syndrome and cytogenetic abnormalities revealed by conventional karyotype and multiplex fluorescent in situ hybridization.
A 63-year-old patient underwent heart transplantation for myocardiopathy in 1985. Azathioprine 100 mg daily was started in 1989 as an immunosuppressive therapy and continued for 11 years culminating in a cumulative dose of 400 g. Pancytopenia was discovered in December 1999 and azathioprine treatment was therefore discontinued. Blood cell count showed a hemoglobin concentration at 8.5 g/dl, MCV 120 fl, white blood cell 1.5 Â 10 9 /l with PMN 0.7 Â 5 Â 10 9 /l, lymphocytes 0.5 Â 10 9 /l, monocytes 0.1 Â 10 9 /l, and platelets 32 Â 10 9 /l. Red blood cells showed massive anisopoïkilocytosis. Reticulocytes were at 37 Â 10 9 /l. Bone marrow aspirate revealed a hypercellular bone marrow with 55% erythroblasts and 3% blasts. Dyserythropoiesis was extreme but only mild signs of dysgranulopoiesis and dysmegacaryopoiesis were initially noted. Perls staining revealed 37% ring sideroblasts. Karyotype was 45, XY, der(12;17)(q10;q10), À17, 5 45, XY, del(7)(q11q32) der(12;17)(q10;q10), À17, 5 and 46, XY. 1 Pseudo-Pelger Huet abnormality was observed in a fraction of PMN on peripheral blood smears, as typically described in 17pÀ syndrome. Immunocytochemistry with anti-P53 monoclonal antibody revealed overexpression of P53 protein, suggesting P53 mutation of the remaining allele. However, direct sequencing of exons 5-8 of the P53 gene did not allow us to identify the mutation. Anemia and thrombocytopenia rapidly worsened and transfusions of four red blood cell units in a month combined with daily injections of desferoxamine were necessary. Androgen and erythropoietin treatment were also tried, but only little improvement of cytopenia could be observed. In November 2000, leukemic blasts appeared in the peripheral blood. Severe bleeding led to death of the patient on December 16, 2001.
Although many patients have been exposed for a long time to continuous treatment with azathioprine, few cases of t-MDS or AML have been reported, suggesting that this drug is weakly leukemogenic and that additional factors or individual susceptibilities may be implicated in leukemogenesis. In this way, it is worth noting that our patient did not present mutation of the thiopurine S-methyltransferase, the enzyme that inactivates azathioprine, suggesting that the disease was not associated with accumulation of the drug. Common characteristics of the therapy-related MDS/AML induced by azathioprine share most of the features observed in t-AML/MDS following prolonged exposure to alkylating agents. These include complex karyotype with frequent loss of chromosome 7, severe cytopenia, preceding phase of MDS before AML, and are often associated with an extremely poor outcome. However, to our knowledge, the case reported here is the first one of 17pÀ MDS syndrome following azathioprine treatment. This is in agreement with the hypothesis that azathioprine may share common mechanisms of genotoxicity with alkylating agents. 
